BOEHRINGER INGELHEIM TAPS OWKIN AI FOR DRUG DISCOVERY

The agreement marks Boehringer Ingelheim's entry into a growing trend of pharmaceutical companies leveraging machine learning for drug development. Owkin's AI model assists in identifying and validating new drug candidates across multiple therapeutic areas. Boehringer Ingelheim joins AstraZeneca and Sanofi as prominent pharmaceutical partners utilizing Owkin's technology. The platform analyzes complex biological data to accelerate the discovery process, potentially reducing development timelines and costs. Owkin, founded in 2016, combines federated learning with medical data to train AI models for drug discovery. The company has raised significant funding to expand its partnerships with major pharmaceutical companies seeking to integrate AI into their research pipelines. The deal underscores the pharmaceutical industry's shift toward AI-assisted drug development as companies compete to bring new treatments to market more efficiently. Oncology and immunology remain high-priority therapeutic areas due to continued demand for novel treatment options.